1.Product Overview

Product Name	Rosuvastatin Calcium Tablets, USP
Reference Listed Drug (RLD)	Crestor® (AstraZeneca)
Pharmaceutical Form	Film-coated tablet
Strength	5 mg, 10 mg, 20 mg, 40 mg

2.Indications and Usage

Rosuvastatin is an HMG-CoA reductase inhibitor indicated for:

Hyperlipidemia	As an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, non-HDL-C, and triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.
Homozygous Familial Hypercholesterolemia (HoFH)	To reduce LDL-C, total-C, and ApoB in adult patients.
Primary Prevention of Cardiovascular Disease	To reduce the risk of stroke, myocardial infarction (MI), and arterial revascularization procedures in adult patients without clinically evident coronary heart disease but with an increased risk (based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor).

3.Dosage and Administration

Important Administration Instructions	Rosuvastatin can be taken with or without food, at any time of the day.
	The dose range is 5 mg to 40 mg once daily. The usual starting dose is 10-20 mg once daily.
	The 40 mg dose is restricted to patients who do not achieve their LDL-C goal with 20 mg.
Special Populations	Asian Patients Consideration should be given to initiating therapy with 5 mg once daily due to increased rosuvastatin plasma concentrations.
	Renal Impairment Dose adjustments are necessary for patients with severe renal impairment.

4.Comparison of Commonly Prescribed Statins

Feature	Rosuvastatin	Atorvastatin	Simvastatin
Mechanism of Action	HMG-CoA Reductase Inhibitor	HMG-CoA Reductase Inhibitor	HMG-CoA Reductase Inhibitor
Statin Intensity (Potency)	High-Intensity (10-40 mg) (Most potent on a mg-per-mg basis for lowering LDL-C)	High-Intensity (40-80 mg) Moderate-Intensity (10-20 mg)	Moderate-Intensity (20-40 mg) (80 mg dose is restricted due to myopathy risk)
Pharmacokinetics	Hydrophilic (water-soluble) (Lower potential for non-CYP450 metabolism)	Lipophilic (fat-soluble) (Metabolized by CYP3A4)	Lipophilic (fat-soluble) (Metabolized by CYP3A4; many drug interactions)
Elimination Half-Life	Long (~19 hours)	Long (~14 hours)	Short (~3-5 hours)
Dosing Time	Any time of day (due to long half-life)	Any time of day (due to long half-life)	Evening (recommended, due to short half-life and cholesterol synthesis patterns)

5.Advantages of SPH Rivaroxaban Tablets

Cost-Effectiveness	Significantly reduces the treatment cost compared to the brand-name drug (Crestor®), making long-term therapy more accessible and sustainable for patients and healthcare systems.
Therapeutic Equivalence (A-Rated)	As an FDA-approved generic (ANDA 207408), it is bioequivalent to Crestor®, guaranteeing the same high standards of safety, efficacy, and pharmacological performance.
cGMP Manufacturing Standards	Manufactured in strict accordance with the FDA's Current Good Manufacturing Practices (cGMP), ensuring consistent product quality, purity, and potency.